Last reviewed · How we verify
NCT07303712
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
trial in Hepatocellular Carcinoma (HCC) in 12 participants. Currently enrolling.
1 August 2026
Quick facts
| Lead sponsor | Palo Alto Veterans Institute for Research |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 12 |
| Start date | 1 August 2024 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across United States |
Conditions studied
- Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
Sponsor
Palo Alto Veterans Institute for Research
Who can join
18 and older, any sex, with Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07303712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma (HCC)
Currently open trials in the same condition.
- NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
Other Palo Alto Veterans Institute for Research trials
Trials by the same sponsor.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT06704061 — Online Yoga vs Acceptance and Commitment Therapy for Treating Chronic Musculoskeletal Pain · NA · recruiting
- NCT07069517 — Accelerated Treatment for Co-occurring Insomnia, Nightmares, and PTSD · NA · recruiting
- NCT07303725 — Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology · recruiting
- NCT06566976 — Prehabilitation and Rehabilitation in PAD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07303712 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Palo Alto Veterans Institute for Research
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07303712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing